As in vitro diagnostics (IVD) manufacturers consolidate to chase high-margin precision medicine, medical laboratories must learn to navigate a market split into two distinct tiers: commodity-driven volume testing and high-value, data-driven genomics. That was a key message from an IVD panel convened at the 2026 Executive War College on Diagnostics, Clinical Laboratory, and Pathology Management. […]
What ‘White Collar/Blue Collar’ Testing Split Means for Labs
Panel explains that as the IVD market shifts, genetic tests separate from core services
- By Scott Wallask
- > From the Volume XXXIII, No. 8 - June, 2026 Issue
